Previous 10 | Next 10 |
Mario13/E+ via Getty Images Arcturus wins new bullish call at Cantor on experimental COVID-19 shot Arcturus Therapeutics (ARCT) has added ~1.3% in the pre-market after Cantor Fitzgerald initiated its coverage with an overweight recommendation highlighting the company’s effort...
Gainers: Alterity Therapeutics Limited (ATHE) +68%.TRxADE HEALTH (MEDS) +57%.Marin Software (MRIN) +45%.Bridgeline Digital (BLIN) +35%.Birks (BGI) +25%.Pulse Biosciences (PLSE) +25%.SGOCO Group (SGOC) +22%.Grid Dynamics Holdings (GDYN) +19%.scPharmaceuticals (SCPH) +18%.U.S. Silica Holdi...
Shares of Novocure (NASDAQ: NVCR) were sliding 15.1% lower as of 11:05 a.m. EDT on Thursday. The decline came after the company announced final results from its phase 2 study evaluating a combination of its Tumor Treating Fields (TTFields) therapy with sorafenib in treating advanced...
Gainers: Alterity Therapeutics (ATHE) +103%, TRxADE HEALTH (MEDS) +62%, Pulse Biosciences (PLSE) +22%, Spero Therapeutics (SPRO) +12%, Kintara Therapeutics (KTRA) +6%.Losers: Citius Pharmaceuticals (CTXR) -21%, Aligos Therapeutics (A...
Borqs Technologies (BRQS) -17%.Verb Technology (VERB) -15%.CureVac (CVAC) -13% on final data from phase 2b/3 trial on COVID vaccine.1stdibs.Com (DIBS) -12%.Newegg Commerce (NEGG) -11%.Weidai (WEI) -11%.NovoCure (NVCR) -10% after final results from mid-stage TTFields liver ...
Disease control rate was 76% with 9.5% objective response in a patient population with poor prognosis and limited exposure to study treatments In patients who completed at least 12 weeks of Tumor Treating Fields treatment, disease control rate was 91% with 18% objective respon...
In 2020 alone, almost 10 million people lost their battle against cancer. However, oncology company NovoCure (NASDAQ: NVCR) and its new category of cancer treatment is improving the lives of patients. And with 1,100% gains since its IPO, it's also improving investors' lives....
Novocure (NVCR) announces that it has advanced a new, flexible torso array into a clinical usability study.The updated array will be tested by patients and their caregivers at four clinical sites in Europe.The new design is intended to improve skin adhesion, to increase degrees-of-motion...
New array intended to increase ease-of-use for torso and abdominal applications Novocure (NASDAQ: NVCR) today announced it has advanced a new, flexible torso array into a clinical usability study. The updated array will be tested by patients and their caregivers at four clin...
As it harnesses the power of an electromagnetic field, NovoCure offers hope to countless patients suffering from aggressive cancers. Tumor Treating Fields are now approved for deadly cancers, including glioblastoma multiforme and mesothelioma. The sales also are heading toward the blo...
News, Short Squeeze, Breakout and More Instantly...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...